Anna Brown

The Eu­ro­pean Com­mis­sion is ask­ing bio­phar­ma and man­u­fac­tur­ing com­pa­nies about their re­ac­tion to No­vo Hold­ings’ pro­posed ac­qui­si­tion of Catal­ent, ac­cord­ing to Reuters. While the EC

Ther­mo Fish­er is clos­ing a fac­to­ry in Lex­ing­ton, MA, and merg­ing op­er­a­tions with a new­er fa­cil­i­ty in Plainville, MA, to “op­ti­mize” vi­ral vec­tor pro­duc­tion, a

Wel­come to End­points News’ man­u­fac­tur­ing briefs, where we bring you es­sen­tial news on new builds, col­lab­o­ra­tions, re­calls and more. Co­herus is Sign up to read

Catal­ent re­port­ed a slight rev­enue up­swing dur­ing its lat­est quar­ter­ly re­sults, which CEO Alessan­dro Masel­li at­trib­uted to “cus­tomers’ con­tin­ued con­fi­dence” in the CD­MO. Yet the

The Eu­ro­pean Com­mis­sion has set Dec. 6 as its dead­line to de­cide if No­vo Hold­ings’ mul­ti-bil­lion-dol­lar ac­qui­si­tion of Catal­ent pass­es its an­titrust re­view, ac­cord­ing to